DCGI OKs phase-1 trial of Reliance Life Sciences' COVID vaccine
New Update
BY A STAFF REPORTER
The national drug regulator has granted approval to Reliance Life Sciences Ltd to conduct phase-1 clinical trials of its recombinant protein-based COVID-19 vaccine, The Economic Times reported, citing sources.
The subject expert committee under the regulator reviewed the application at a meeting on Thursday and approved trials of the company's two-dose COVID-19 vaccine.
The company, a subsidiary of Reliance Industries Ltd, develops biosimilars, oncology generics, regenerative medicine including stem cells therapies, and molecular medicine, among others.
The company's COVID-19 vaccine is similar to the one being developed by Hyderabad-based Biological E Ltd.
/anm-english/media/agency_attachments/AtBG5e3MoE629QYzhZen.png)
/ )
/anm-english/media/post_banners/MSJUOCdT3VcIfQAGG3mj.jpg)